Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) saw a significant increase in short interest in September. As of September 30th, there was short interest totalling 31,500 shares, an increase of 107.2% from the September 15th total of 15,200 shares. Based on an average daily trading volume, of 45,200 shares, the short-interest ratio is currently 0.7 days. Approximately 2.3% of the company’s shares are sold short.
Hedge Funds Weigh In On Avenue Therapeutics
A hedge fund recently bought a new stake in Avenue Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned approximately 7.97% of Avenue Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 17.34% of the company’s stock.
Avenue Therapeutics Trading Up 2.0 %
Avenue Therapeutics stock traded up $0.04 during trading hours on Friday, hitting $2.06. 7,020 shares of the stock traded hands, compared to its average volume of 58,539. Avenue Therapeutics has a one year low of $1.90 and a one year high of $45.75. The firm’s 50-day moving average price is $2.54 and its two-hundred day moving average price is $4.35. The company has a market cap of $2.95 million, a PE ratio of 0.08 and a beta of -0.17.
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.
Further Reading
- Five stocks we like better than Avenue Therapeutics
- How to Invest in Insurance Companies: A Guide
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Energy and Oil Stocks Explained
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- Basic Materials Stocks Investing
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.